Meeting automnal du GDR ACCITH à Montpellier les 26-27 Novembre 2013


Chaque année, le GDR ACCITH organise pour ses membres, des rencontres qui sont ouvertes à toute la communauté scientifique.Organisé par les équipes montpelliéraines du GDR, le meeting automnal aura lieu au Corum de Montpellier, salon du belvédère, les 26 et 27 novembre 2013 (informations pratiques) et se déroulera en:

  • Journée Interne  (réservée aux membres du GDR ACCITH):

Mardi 26 novembre 2013 09:30 – 19:00

Les appels à communication débuteront courant septembre.

Priorité sera donnée aux jeunes chercheurs (doc/post-doc) afin de favoriser les échanges et les mobilités entre partenaires du GDR. Cette journée interne inclura également des « speed présentations » des nouveaux membres du GDR.

Dîner 20:00

  •  Journée Externe (ouverte à tous):

Télécharger le programme

Télécharger le bulletin d’inscription

Mercredi 27 novembre 2013 08:30 – 17:30

The research network on Antibodies and Therapeutic Targeting (GDR 3260 « Anticorps et ciblage thérapeutique ») is pleased to announce its 2013 Forum which will be held in Montpellier on November 27th. Devoted to therapeutic antibodies against cancer: tools and models to understand and improve their efficacy, the meeting will gather international experts who will exchange their point-of-view on the state-of-the-art and perspectives of this therapeutic domain.

The forum will start by a panorama given by Veronique Blanc, Sanofi Oncology, on the therapeutic antibodies currently used in the clinic, the potentials, the challenges and the limitations. One of the improvement option being the development of innovative antibodies with original properties, James D Marks, University of California, will present his strategies for the isolation of internalizing antibodies. As a model for a better evaluation of humanized or human antibodies and in order to understand their mechanisms of action, Anja Wege, Univ Regensburg, will present her Human Tumor Mouse model. To ensure an optimal selection of the patients based on functional tests, Fabien Gaire, Global Head Pathology and Tissue Analysis, Roche Diagnostics, will introduce companion tests beyond IHC. Since the ultimate option for patient selection could be in vivo imaging, Caroline Rousseau, Nantes, will present immunoTEP data using 68Ga-labeled bispecific antibodies. Hans van der Vliet,VU University Medical Center, Amsterdam, will explain innate immune cells could be exploited to enhance anti-cancer antibodies efficiency. As another option to improve therapeutic antibodies being their radiolabeling, Jean-Marc Le Doussal, Atlab Pharma, Nantes, will present a clinical trial using 177lutetium-labeled J591 in patients with androgen-independent prostate cancer.

Beyond these 7 invited speakers, 3 oral presentations will be selected from the GDR’s research groups based on their relevance for the topic and the attractiveness of their results.

Scientific program

08:00 | 08:45 Welcome

08:45 | 09:00 Introduction

09:00 | 10:30 Session 1

Panorama on the therapeutic antibodies currently used in the clinic, the potentials, the challenges and the limitations
Véronique Blanc, Head of Biologics Discovery, Oncology Sanofi

Strategies for the isolation of innovative and original antibodies
James D Marks, School of Medicine, University of California, San Francisco, USA

10:30 | 11:00 Coffee break

11:00 | 12:30 Session 2

The power of humanized mice in translational research
Anja Kathrin Wege, Dpt. of Gynecology and Obstetrics, Caritas Hospital St. Josef, University of Regensburg, Germany

 Personalized medicine for the next generation therapies: Challenges and new Strategies
Fabien Gaire, Global Head Pathology and Tissue Analysis, Roche Diagnostics, Germany

12:30 | 14:00 Lunch

14:00 | 15:00 Selected abstracts: 3 x 20 minutes

15:00 | 17:15 Session 3

ImmunoPET using pretargeted peptide labeled with 68Ga in CEA positive tumors

Caroline Rousseau, Nuclear Medicine Department, Comprehensive Cancer Center ICO, Gauducheau, Saint Herblain, France

Exploiting innate immune populations to enhance the efficacy of therepeutic antibodies in cancer
Hans van der Vliet, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

ATL101 (Lutetium-177 huJ591 anti-PSMA mAb) clinical results in M+ castrate resistant prostate cancer patients
Jean-Marc Le Doussal, Atlab Pharma, Nantes, France


Scientific committee

Azria David

Cartron Guillaume

Cerutti Martine

Chardès Thierry

Larbouret Christel

Lefranc Marie-Paule

Martineau Pierre

Navarro-Teulon Isabelle

Pèlegrin André

Pelegrin Mireia

Poul Marie-Alix

Robert Bruno

Watier Hervé

Organization committee

Daguet Arnaud

Gauvineau Annie

Bonnemaison Marc